EVANIUM Raises €2.2 Million in Seed Funding
EVANIUM, a life-science company based in Regensburg, Bavaria, has successfully closed a €2.2 million Seed funding round. Specializing in the development of functional ingredients, EVANIUM utilizes its proprietary drug delivery platform, OPTISOLV®, to improve the solubility, stability, and bioavailability of nutraceutical ingredients.
Investors and Leadership
The Seed funding round was led by FoodLabs, with additional participation from Feast Ventures. The company was founded in 2019 by Felix Rolka and David Ofner, who serve as Co-Founder & Managing Director and Co-Founder & CTO, respectively.
Strategic Use of Funds
EVANIUM plans to allocate the newly raised funds to scale up its OPTISOLV® technology. The company aims to expand its team and advance clinical studies. Additionally, the funding will be used to strengthen commercial partnerships across sectors such as nutraceuticals, nutricosmetics, and functional foods.
About EVANIUM's Technology
EVANIUM's OPTISOLV® platform addresses a significant challenge in the nutraceutical industry: the limited absorption of active ingredients. By enhancing ingredient absorption and effectiveness, the platform enables the creation of high-performance, clean-label products. This innovation positions EVANIUM at the forefront of developing more efficient and effective nutraceutical solutions.
Future Prospects
With this infusion of capital, EVANIUM is well-positioned to make substantial advancements in the nutraceutical field. The company's focus on enhancing ingredient absorption could lead to more effective supplements and functional foods, offering greater value to consumers and partners alike.
For more information about EVANIUM and its innovative solutions, visit their website.